ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GALT Galectin Therapeutics Inc

2.39
-0.02 (-0.83%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 57,692
Bid Price 2.01
Ask Price 2.45
News -
Day High 2.4297

Low
1.28

52 Week Range

High
2.4799

Day Low 2.30
Company Name Stock Ticker Symbol Market Type
Galectin Therapeutics Inc GALT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -0.83% 2.39 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.38 2.30 2.4297 2.39 2.41
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
498 57,692 $ 2.37 $ 136,568 - 1.28 - 2.4799
Last Trade Time Type Quantity Stock Price Currency
19:43:02 25 $ 2.40 USD

Galectin Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
147.2M 61.85M - 0 -38.87M -0.63 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Galectin Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GALT Message Board. Create One! See More Posts on GALT Message Board See More Message Board Posts

Historical GALT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.202.47992.192.41147,7770.198.64%
1 Month1.942.47991.8952.17106,5530.4523.20%
3 Months1.682.47991.591.9872,7510.7142.26%
6 Months1.832.47991.5551.9468,7560.5630.60%
1 Year1.932.47991.281.8261,2170.4623.83%
3 Years2.135.701.023.02484,4410.2612.21%
5 Years4.655.701.023.05401,277-2.26-48.60%

Galectin Therapeutics Description

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Your Recent History

Delayed Upgrade Clock